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X-linked West syndrome, also called “X-linked infantile spasms” (ISSX), is characterized by early-onset generalized
seizures, hypsarrhythmia, and mental retardation. Recently, we have shown that the majority of the X-linked families
with infantile spasms carry mutations in the aristaless-related homeobox gene (ARX), which maps to the Xp21.3-
p22.1 interval, and that the clinical picture in these patients can vary from mild mental retardation to severe ISSX
with additional neurological abnormalities. Here, we report a study of two severely affected female patients with
apparently de novo balanced X;autosome translocations, both disrupting the serine-threonine kinase 9 (STK9) gene,
which maps distal to ARX in the Xp22.3 region. We show that STK9 is subject to X-inactivation in normal female
somatic cells and is functionally absent in the two patients, because of preferential inactivation of the normal X.
Disruption of the same gene in two unrelated patients who have identical phenotypes (consisting of early-onset
severe infantile spasms, profound global developmental arrest, hypsarrhythmia, and severe mental retardation)
strongly suggests that lack of functional STK9 protein causes severe ISSX and that STK9 is a second X-chromosomal
locus for this disorder.
Introduction
Infantile spasms are frequent, with incidence rates sim-
ilar among different populations studied, ranging from
2 to 5 per 10,000 live births. Mental retardation occurs
in 70%–90% of patients with infantile spasms (for re-
view, see Wong and Trevathan 2001). Generally, the on-
set of infantile spasms is during the 1st year of life.
Spasms tend to occur in clusters and usually involve
the muscles of the neck, trunk, and extremities. Other
neurological abnormalities, such as cerebral atrophy,
structural malformations, and hydrocephalus, are often
reported. Many of these patients have neurological im-
pairment prior to the onset of spasms, and their intel-
lectual prognosis is generally poor. Infantile spasms syn-
drome, or what is often referred to as “West syndrome”
(WS), is characterized by the triad of infantile spasms
(as a seizure type), hypsarrhythmia, and severe-to-pro-
found mental retardation (Wong and Trevathan 2001).
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Although most cases of infantile spasms are sporadic,
at least some familial cases exist and have been studied.
Among these is the form of X-chromosome–linked WS,
or X-linked infantile spasms (ISSX [MIM 308350]). Re-
cently, we have identified the underlying defect in four
unrelated families with ISSX (one from each of the
following sources: Strømme et al. [1999], Claes et al.
[1997], Bruyere et al. [1999], and our observations of
one small unpublished family with ISSX) by finding mu-
tations in the ARX gene, an X-linked homeobox-con-
taining gene, which is the ortholog of the Drosophila
aristaless-related homeobox gene (Bienvenu et al. 2002;
Strømme et al. 2002b). Only one previously published
family with ISSX (family B reported by Claes et al.
[1997]) did not have a mutation in the ARX gene
(Strømme et al. 2002b).
In humans, ARX mutations cause various forms of
epilepsy, including infantile spasms, myoclonic seizures,
and peripheral dystonia, as well as syndromic and non-
syndromic X-linked mental retardation (Bienvenu et
al. 2002; Scheffer et al. 2002; Strømme et al. 2002a,
2002b) and lissencephaly with abnormal genitalia (Ki-
tamura et al. 2002).
In the present study, we describe two severely af-
fected, unrelated female patients with apparently bal-
anced X;autosome translocations. In both patients, the
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Figure 1 Patient 1 at the age of 3 years.
X-chromosomal breakpoints are at Xp22.3 and are
therefore distal to ARX, and molecular investigations
have shown that both disrupt the ubiquitously ex-
pressed serine-threonine kinase 9 (STK9) gene. These
observations, as well as functional considerations, sug-
gest that we have identified a second locus for the X-
linked WS/ISSX and thus further elucidated its genetic
heterogeneity.
Subjects and Methods
Subjects
Patient 1 is the second child of healthy unrelated par-
ents. The girl was born—after a normal pregnancy, com-
plicated only by bleeding in the 2nd mo—10 d after
term, with Apgar scores of 9 at 1 min and 10 at 5 min
and with normal birth weight (3,410 g), length, and head
circumference. When the patient was 3 wk old, the par-
ents noted mild hyperexcitability, and when she was 6–8
wk, they noted abnormal turning of the eyes. Initially,
motor development was normal, and electroencepha-
lograms (EEGs) gave normal results. At the age of 3 mo,
EEG showed hypsarrhythmia, and infantile spasms were
diagnosed. At the age of 4.5 mo, tonic-clonic seizures
became more frequent, and motor retardation and gen-
eralized hypotonia were evident. The seizures initially
responded to clonazepam, but, after the age of 5 mo,
antiepileptic drugs could no longer control them. With
time, the seizures evolved into tonic seizures, and, after
the age of 7 years, dyskinesias with short choreatiform
or myocloniclike movements also occurred. The fre-
quency of seizures diminished in the following years, but
the patient made no developmental progress. The patient
had dysmorphic features, with hypertelorism, high nasal
bridge, large but narrow and not well-modeled ears, a
low posterior hairline, and a simian crease (fig. 1). Eye
movements were uncoordinated, and there was no fix-
ation to light or movement. The fundi were pale, with
fine pigmentation. Cranial magnetic resonance imaging
(MRI) at age 6 years showed ventricular enlargement
and hypoplasia of the corpus callosum, cerebellum, and
white matter. There was a mild conduction defect (43
m/s) in the median nerve, but values were normal in the
lower limbs. Urine amino acids and organic acids and
plasma lactate and pyruvate were normal, and GM-1
and GM-2 gangliosidosis were excluded. At age 7 years
and 4 mo, length was 126 cm (50th percentile), weight
was 17.4 kg (!3rd percentile), and head circumference
was 49 cm (3rd percentile). The patient died at the age
of 17 years.
Patient 2 was the first child of unrelated Indonesian
parents. She was born at 38 wk gestation—following a
normal pregnancy, labor, and delivery—with Apgar
scores of 7 at 1 min and 8 at 5 min, head circumference
of 35 cm (50th percentile), and birth weight of 3,000 g
(10th–50th percentile). She was considered to be a nor-
mal child until age 2 mo, when extensor spasms ap-
peared. EEG showed hypsarrhythmia, and a diagnosis
of infantile spasms was made. Results of cerebral com-
puted tomography (CT) and MRI scans were normal.
The child made no developmental progress following the
onset of seizures. With time, the seizures evolved into
tonic seizures (poorly controlled by antiepileptic drugs)
that persisted until her death at 3 years of age. Head
circumference at 14 mo was 46 cm (50th percentile).
Investigations of the following gave normal results: urine
levels of amino acids, organic acids, mucopolysaccha-
rides, and sulfite; cerebrospinal fluid levels of lactate,
glycine, glucose, and protein; leukocyte lysosomal en-
zymes; plasma very-long-chain fatty acids; whole blood;
thyroid function; and visual evoked potentials, electro-
retinogram, and brain stem auditory evoked responses.
A clinical summary of both patients, in comparison
with the features of patients with ARX mutations, as
well as infantile spasms syndrome/WS, is presented in
table 1.
Cytogenetic Investigations and Cosmid Library
Screening
Samples from patients and parents were obtained after
informed consent. Chromosome analysis was performed
using standard high-resolution techniques (Dutrillaux
1981).
Initial FISH experiments were performed with YAC
clones from the region of interest. Fine mapping of
breakpoints was performed with smaller BAC/PAC and
cosmid clones. DNA samples were prepared according
to standard protocols and were labeled with either bi-
otin-16-dUTP or digoxigenin-11-dUTP, by Nick trans-
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Table 1
Clinical Summary of Patients 1 and 2 with Disrupted STK9 Genes, Compared with the Features of Patients with ARX Mutations and
Patients with Infantile Spasms Syndrome/WS
Feature Patient 1 Patient 2 ARX Disorders
Infantile Spasms
Syndrome/WS
Sex Female Female Males Males and females
Mental retardation; severity Yes; profound Yes; profound All; 58% mild-
moderate,
42% severe to
profound
Most (70%–90%);
severe to profound
Seizures Yes Yes 58% All
Presenting seizure type Infantile spasms Infantile spasms Infantile spasms
(59% generalized
tonic-clonic,
34% absence,
3.5% unspecified)
Infantile spasms
Age at onset 3 mo 2 mo Varies by mutation !1 year (usually 3–8 mo)
EEG results Hypsarrhythmia Hypsarrhythmia Hypsarrhythmia in most Hypsarrhythmia in most
Subsequent seizure type Tonic Tonic Generalized tonic-clonic,
absence, myoclonic,
atonic, and complex
partial seizures
30%–50% have another
seizure type (partial,
myoclonic, tonic,
or tonic-clonic)
Other neurological features Dyskinesias with chorei-
form and myoclonic
movements, pale fundi
with fine pigmentation
None Dystonia/Partington
syndrome, autism,
and spinocerebellar
ataxia
Depends on etiology
(e.g., cerebral palsy)
Nonneurological features Mildly dysmorphic facial
features, head
circumference
3rd percentile
Head circumference
50th percentile
Macrocephaly
and microcephaly
Depends on etiology
Familial occurrence No No Common Uncommon
Etiology STK9 mutation STK9 mutation ARX mutation Heterogeneous
lation. Immunocytochemical detection of probes was
performed exactly as described elsewhere (Wirth et al.
1999). Chromosomes were counterstained with 4′6-dia-
mino-2-phenyl-indole (DAPI). Metaphases were ana-
lyzed with a Zeiss epifluorescence microscope.
The spotted Lawrence Livermore X-chromosome–
specific cosmid library was hybridized with a pool of
PCR products of the candidate region. Fragments were
labeled with a32[P]dCTP by random priming. Labeled
probes were preannealed with Cot1 DNA (Gibco) for 1
h at 65C, and they were then hybridized overnight at
the same temperature, washed, and photographed using
Kodak X-Omat AR film.
Molecular Investigations
For Southern blot analysis, genomic DNA from the
patients and control DNAs were digested using BamHI,
EcoRI, HindIII, and EcoRV and were size-separated in
0.7% agarose gels. The DNAs were blotted onto nylon
membranes and were hybridized with a32[P]dCTP-la-
beled random hexamer primed PCR products. For pa-
tient 1, the breakpoint-spanning probe for Southern blot
hybridization was generated using the following PCR
primer set: STK9_F (5′-GTATTTGAAGCCTCCCA-
TCG-3′) and STK9_R (5′-CTAAACTGGCAGAAGCA-
CAGG-3′), (positions 76261–77382 of clone 245G19;
GenBank accession number Z92542). For patient 2, the
1-kb probe for Southern blot hybridization was gen-
erated from genomic DNA (positions 19–930 of the
958B3 clone; GenBank accession number Z93023), us-
ing the following PCR primers: 958B3-F (5′-GGATCG-
GGTTTCCAAGGAGGAT-3′) and 985B3-R (5′-ACTA-
AACTGCAAGTGACTGCAAG-3′), resulting in a 912-bp
amplicon.
Adaptor-ligated PCR was performed as described by
Siebert et al. (1995), using EcoRI-digested patient DNA
and a nested set of primers. Primer sequences are avail-
able, on request, from the authors. Amplified fragments
were isolated on 1% agarose gels and were purified with
Qiagen columns and sequenced.
Total RNA was isolated from fetal brain, fibroblast,
and lymphoblastoid cell lines, using Trizol (Gibco); testis
RNA was purchased from Clontech. RT was performed
with random hexanucleotide primers and Superscript II
(Gibco). In each experiment, DNA contamination was
excluded by amplifying samples in parallel without the
addition of RT. For patient 1, STK9 expression was an-
alyzed with the following primer sets: 5BP-F (5′-TGAA-
AGTTCCCACCAACCAG-3′) (located in exon 2) and
5BP-R (5′-AAGTAAGAGTTCTGGGGACC-3′) (located
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Table 2
Primer Sequences and Conditions for the PCR Amplification of the STK9 Exons from Genomic DNA
EXON FORWARD PRIMER REVERSE PRIMER
PRODUCT
SIZE
(bp)
OPTIMAL CONDITIONS
Mg2
Temperature
(C)
1 CTCTCC AGC CCA GGT TGC TAG GGT CTC CAC TCT CAG GAG AAG C 506 1.5 60
2 TAA GAT TGG TAC TAG AGT ACT GC GAC ACA CAT GTG AAT TGA TAT AGG 412 1.5 60
3 GAG AAG CAA TGT CAG TAT AGC AG CAT GCC CAC ACG CAA AGA CCA C 194 1.5 60
4 CAA CTG GAA TCC CCA GTC GGA AGT GTC TGA CCA GCT AGA TCC 222 .5 60
5 GAA GTA CTC AAA GCA GAA GGT GA TCG GGC AAA TGT GCA CAT TGG C 285 .5 60
6 GCT CTG TAT TGG ATG AAT TAT TCT AG GAC AGT AAC ATG TGA AAT ACT CTT AAC 297 1.5 55
7 CAG TGT CAA TCA GGA GAA CAT AG TAA TTC TGT AAG TAC CAG GAC TTA 163 1.5 55
8 GCC CAT GCG AGA ACA GTC ATT AC GCA AAT GAC AAT AGA ATC AGC AG 280 1.5 55
9 AGT TGC CAA AAT AAT CTC TTC CTT GAA CAA TGA CTC AAA TAC TGC AG 284 1.5 55
10 AAC ACT CAC AAG CAC GTG CA TTA TTT GCC ATT CCA CAT CTC CT 273 1.5 55
11 GAC TTT GTA ATG TTC TTA ACG ATC CTA ATT GCA TCA TTT AAG CAG CC 281 1.0 60
12 TTG TGT GTC AGC TAT TGA GGG GGT ATG TTG TTG TTG GTG AGA TC 284 1.5 55
12a TGC ACA CCA AAA CCT ACC AAG C GCT TTT GGC CTT GGT CCT GTA GGA 329 1.5 55
12b GAG TCG GCA TAG CTA TAT TGA CAC GAA TGG CTA CTG TCC ATG TGC 354 1.5 55
12c AAC GCT GGA CTC ACG TCG AAC CCA CCA GAT TCA GTC AAG GTG 318 1.5 55
13 CTG GTT ATG GTC CTA GTT CTA CC GTG GGA GAC TGG GTA TTA ATA C 285 1.5 55
14 CAT AGG CAA TAT TGT CAT CAA TGT G GTG TAG GTG AGA AGG CCG CTG 269 2.0 60
15 GAA AAG TCC ATC AGT GAC TTA C GGA CAC TAA AAA GCT CAT CCA GA 249 1.5 55
16 GGC TAT AGG AAC CTA GTG TCA TG AAG TGC AAA GTG TAA AGT ATC CAT 282 1.5 55
17 CTC CTC TTG GGT GTG GTT GC GCT CAG CCT TAC TGT AAC ATT G 312 1.0 60
18 TCT AAC TTG AAT CCT GTG TGC TCC TGG TCA CAG AGG ACA CAT G 301 .5 58
19 GTG GGC AGA AGT GGC CAA TA GTC TAG GGT CGT TAT GGC AGC 223 1.0 58
20 ACC TTG GCT TCA GCT GGT GTC GGG CAA TTC CGA GGT ACA GC 325 2.0 60
21 GCC AGA GTG CAC CTG CTA GC AAG GAA AAC TCA ACC TCA GCG 286 1.0 58
in exon 8), with an amplicon of 678 bp; BPf 5′-TGGGC-
TGTATTCTTGGGGA-3′ (located in exon 9) and BPr
5′- TTCTCGTGTCACTGTGTCTG-3′ (located in exon
12), with an amplicon of 1,029 bp; 3BPf 5′-GTCAAAG-
AGACCTCCAGAGA-3′ (located in exon 13) and 3BPr
5′-GGGGTGAATCCGAATTTCTG-3′ (located in exon
18), with an amplicon of 645 bp.
For patient 2 the following STK9 gene-specific prim-
ers, flanking the ATG translation start site, were used;
STK9.1 5′-GTTCCCACCAACCAGTGAGAA-3′ (located
in exon 2), and STK9.2 5′-TTTAAGTACAACTCCAT-
AGGCTC-3′ (located in exon 3). The STK9.1/STK9.2
primers amplify a 208-bp amplicon only from cDNA.
As a control of the integrity of the isolated RNA, esterase
D (ESD)–specific primers were used, as described else-
where (Ge´cz et al. 1997).
Expression of STK9 isoform II–containing exons 1a
and 1b was investigated with primer set STK9.1a 5′-
AGACCCTACAGGAAGTTGAG-3′ (located in exon
1a) and 5BPr (located in exon 8; see above), followed
by seminested amplification with primers STK9.1a and
STK9.ex8 5′-CCATCTGGTGGCACGTAC-3′ (located
in exon 8).
For patient 1, ARX expression was analyzed with the
following primer set: (ARXcF2 5′-CGCTCGACTCCGC-
TTGGACTG-3′) and ARX0-5R (5′-GAGTGGTGCTGA-
GTGAGGTGA-3′), followed by seminested PCR with
ARXcF2 and ARXcE5STOPR 5′-GCAGCCTTTAGCA-
CACCTCCT-3′. Amplification was performed in the
presence of DMSO. STK9 mutation screening has been
performed using the intronic primers and PCR condi-
tions listed in table 2. ARX gene mutation screening has
been performed by SSCP (primers are available upon
request from J.G.).
Results
Karyotypes
Patient 1 carried a balanced translocation between
the distal short arm of chromosome X and the distal
short arm of chromosome 7. Her karyotype was
46,X,t(X;7)(p22.3;p15). The ideogram is depicted in fig-
ure 2A. Patient 2 carried a balanced translocation be-
tween the distal short arm of chromosome X and the
proximal short arm of chromosome 6. Her karyotype
was 46,X,t(X;6)(p22.3;q14) (see fig. 2B). Neither trans-
location was detected in the parents; thus, both were
considered as de novo translocations. The X-inactivation
pattern was studied cytogenetically and molecularly for
both patients. These experiments indicated 100% in-
activation of the normal X chromosome (results not
shown). For patient 2, complete skewing of the normal
X chromosome was also further supported by the STK9
RT-PCR experiments, which showed complete absence
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Figure 2 FISH mapping of the Xp22.3 translocation breakpoints. A, Ideograms of chromosomes X and 7 and their derivatives der(X)
and der(7) in patient 1 with 46,X,t(X;7)(p22.3;p15), with indications of breakpoints (arrows). B, Ideograms of chromosomes X and 6 and their
derivatives der(X) and der(6) in patient 2 with 46,X,t(X;6)(p22.3;q14). C, FISH analysis of the patient’s chromosomes with the breakpoint-
spanning clone RP1-245G19, which shows signals on the normal X chromosome, the der(X), and the der(7) (arrows). Cohybridization with
an Xptel-specific cosmid probe was used to indicate the normal and derivative X chromosomes (arrowheads). Arrows point to the breakpoints.
D, The metaphase shows the breakpoint-spanning PAC J659D24 with signals on the normal X chromosome and split signals on the very large
derivative X and the derivative chromosome 6.
of the STK9 transcript from lymphoblastoid RNA (see
below and fig. 3C).
Cytogenetic Studies
Initially, breakpoints were investigated by FISH. The
X chromosomal breakpoints were mapped with a set of
cytogenetically and genetically anchored YACs, 18–26
cM, established at the Mendelian Cytogenetic Network
(MCN) Reference Center. In patient 1, signals from the
overlapping YAC 939h7 were found on both derivative
chromosomes, whereas YAC 935f7 gave a signal only
on der(7), and YAC 742h9 gave a signal only on der(X).
In patient 2, hybridization signals of YAC 896f9 ap-
peared only on the der(6), and YAC 960a5 showed sig-
nals only on the der(X). The results placed both X
chromosomal breakpoints within the interval between
markers DXS1195 and DXS999 (results not shown).
Subsequent FISH with BAC and PAC clones from the
DXS1195–DXS999 region further narrowed the posi-
tions of both translocation breakpoints. In patient 1,
PAC RP1-245G19 (Z92542) showed split signals; in pa-
tient 2, the more distally located PAC J659D24 (War-
neke-Wittstock et al. 1998) overlapped the breakpoint.
The results are shown in figures. 2C and 2D. PAC RP1-
245G19 contains all but exons 1, 1a, 1b, 2, and 3 of
STK9, a pseudogene similar to a-1 protein, and the 3′
end of the XLRS1 gene (X-linked juvenile retinoschisis
precursor protein). In patient 1, further refinement of
the breakpoint was achieved by FISH mapping the
cosmid clones LANLc153A2441 and LANLc153P0827,
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Figure 3 A, Diagram of the genomic structure of the STK9 gene and selected clones used for breakpoint mapping by FISH. Exons
(unshaded boxes) and introns are not drawn to scale. The respective positions of the two breakpoints studied, (t(X;7)(p22.3;p15) and
t(X;6)(p22.3;q14), are indicated on top. The lower panel shows a restriction map of the area surrounding both breakpoints, with probes used
for Southern blot hybridization indicated as solid rectangles. Position and size of the normal restriction fragments detected by the two probes
is indicated (B p BamHI, E p EcoRI, H p HindIII, EV p EcoRV). B, Southern blot analysis, using the probes indicated as solid rectangles
in the lower panel of A. Patient DNA—with (tX;6) and t(X;7)—and control DNAs (F p female, M p male) were digested with the indicated
enzymes. Rearranged (junction) fragments (arrows) are present only in the patients but not in the controls. C, RT-PCRs in patients’ lymphoblastoid
(tX;6) and fibroblast (tX;7) RNAs and control RNAs (C p control lymphoblastoid cell line RNA in case of t(X;6), C p control fibroblast
RNA in case of t(X;7), iBr mRNA p infant brain mRNA, gDNA p genomic DNA, M p size marker). The left side of this panel shows a
specific STK9 amplification product of 208 bp (primers STK9.1 and STK9.2, see “Subjects and Methods” section) in all control RNAs but not
in patient RNA. The low molecular weight band visible in almost all lanes represents the primer dimer product. The esterase D (ESD) gene
served as a control for patient cDNA established from mRNA and total RNA. The right side shows specific RT-PCR products of 678 bp with
a primer set spanning STK9 exons 1–10 in both patient and control RNA. Primers spanning the breakpoint (located in exons 9 and 12) amplify
STK9 transcripts of 1,029 bp in the control but not in the patient. D, Chromosome X, 7, der(X) and der(7) sequences at the breakpoints in
patient 1. Chromosome X–derived sequences are shown in bold. The breakpoints are on either side of the common 3-bp sequence (shaded
boxes).
which were positive in a screen with PCR products from
the candidate region. Cosmid LANLc153A2441 showed
signals on the der(7), and cosmid LANLc153P0827
showed signals on the der(X), thereby narrowing the
breakpoint region to a small interval (results not shown).
The breakpoint on chromosome 7 was similarly
characterized. YAC 743f9 (at 63–65 cM, with mark-
ers AFMA283XF5, D7S671, D7S691, D7S2548, WI-
620, and D7S2746) hybridized strongly to der(7) and
weakly to der(X), whereas YAC 776a4, which has at
least the marker D7S691 in common, showed signals
only on der(7), and YAC 956e1 (at 61 cM) gave signals
only on der(X). We then narrowed the chromosome
7 breakpoint to the 600-kb interval between PAC
RP5-953B5 (GenBank accession number AC004934)
and BAC RP11-706L12 (GenBank accession number
AC073852). We did not investigate the chromosome 6
breakpoint of patient 2.
STK9 on Xp22.3 Is Truncated in Two Female Patients
with X;Autosome Translocation
In patient 1, Southern blot hybridization with a PCR
product of clone RP1-245G19 detected two aberrant
fragments in each digest but not in control DNA (fig.
3B, right panel), indicating that this probe is spanning
the breakpoint. Cloning of the der(X) junction fragment
was performed by ligation-mediated PCR on EcoRI-di-
gested DNA. Sequencing of the specific PCR product
and subsequent alignment with the STK9 gene indicated
that the breakpoint lies in intron 10, around position
77101 or 77104 of clone RP1-245G19 (fig. 3D).
In patient 2, we were able to map the X chromosomal
breakpoint to within 2 kb of genomic sequence around
exon 1 (this is the new STK9 exon 1, not the exon 1
described by Montini et al. [1998]). The PCR-generated
1-kb probe from the end of the clone 958B3 (GenBank
accession number Z93023) detected aberrant fragments
on HindIII and BamHI restriction digests but not on
EcoRI digest (see fig. 3B, left panel). This localized the
breakpoint to a maximum of 2.0 kb of the EcoRI-
BamHI fragment of intron 1 of STK9. The breakpoint
was not further refined.
We have also revisited the complete gene structure
of STK9 by aligning entries from the database and
our cDNA sequence (GenBank accession number
AY217744) with genomic clones RP11-558P14 (Gen-
Bank accession number AL109798) and RP1-245G19
(GenBank accession number Z925542). We thereby
found several discrepancies with the exon number and
sizes given by Montini et al. (1998) (GenBank accession
number Y15057). First, STK9 is composed of 23 exons
and not 20. The first three exons (1, 1a, and 1b) are
untranslated and probably represent two transcription
start sites of the STK9 gene (see fig. 3A, upper panel)
separated by ∼17 kb. Exon 2 contains the ATG trans-
lation start codon, which is also conserved in mouse (J.T.
and V.M.K., unpublished data). Second, exon sizes are
as follows: exon 1 is 111 bp, exon 1a is 73 bp, exon 1b
is 49 bp, exon 7 is 60 bp (as in Fugu genes [Brunner et
al. 1999]), exon 17 is 120 bp, exon 18 is 217 bp, exon
20 is 183 bp, and exon 21 is 198 bp (see table 3).
The STK9 RNA isoform containing exons 1a and 1b
(isoform II) is transcribed at a very low level in human
fetal brain and testis but not in lymphoblastoid cell lines
(ESTs with GenBank accession numbers AL704691
and BI559845 and the mRNA with GenBank acces-
sion number BC036091) (results not shown). In con-
trast, STK9 RNA containing exon 1 (isoform I) is ex-
pressed in a wide range of cells, including human
fibroblasts and lymphoblastoid cell lines, which allowed
us to study its expression in both patients. In patient 1,
RT-PCR experiments with primers located in STK9 ex-
ons 2 and 8 on der(7) resulted in a product of expected
size, whereas no amplification product could be obtained
with breakpoint-flanking primers located in exons 9 and
12 or with primers 3′ to the breakpoint, designed in
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Table 3
Exon Numbers, Splice Junction Sequences, and Exon Sizes of the STK9 Gene
Exon No. 3′ Splice Site 5′ Splice Site
Exon Size
(bp)
1 ACTCGGCGGGgtgagtagtc 111
1a GGAAGTTGAGgtatcatatc 73
1b tggtgtccagCTGTACTCTC CTCCCTTCAGgtactctcct 49
2 tttttttcagGGAGTCATTT GTAGGTGAAGgtaagttgga 126
3 tttattatagGAGCCTATGG CAGACACAAGgcaagtacat 35
4 tcccttgcagGAAACACATG GACAGTGAAGgtagatatat 46
5 tacattctagAAAATGAAGA TGTTGAAAAAgtaagtcatt 137
6 taatttttagAATATGCTCG GTCCATCGAGgtgagtatga 121
7 gacactccagATATAAAACC TGTGACTTTGgtaagttaaa 60
8 tatctttcagGTTTTGCTCG TCTTACTTGGgtgagttacc 91
9 tatttttcagCGCTCCCTAT TGGGCTCCGGgtaagaggtt 190
10 tgtctcacagTTTCCAGCTG CCTAATGAAGgtaaggccaa 81
11 atttcctaagAATTTACTGA TGTCTAATAGgtaaatattc 152
12 tttaacatagAAACCAAGCC GTCACCCCAGgtacagttga 967
13 ttacttccagCCTGGAGAAC GAAGTCTGAGgtatgtcaca 102
14 cctgcctcagGGTGGACTGT TTTTACAGAGgtaagcccac 106
15 ctttattcagTGCCATCTCC TCGATCCATGgtgagcattt 124
16 tctcatttagGAAAAGTCCT ATCTCAAACAgtaagtagat 100
17 tttgctctagGTACCCAATT GCAGACCCAAgtgagtggat 120
18 tttctttcagAGCCAGCCAT CAGCTGCCAGgtcagatgga 217
19 caccaactagACGGTGGATG GAACAACAAGgtagagtctg 84
20 tattttccagGAGAATACTT CAGCAATCCGgtaagcagag 183
21 tgctttccagGGTTCTCTTT 198
NOTE.—Lowercase letters indicate intron sequence; uppercase letters indicate exon
sequence; and underlining indicates consensus dinucleotides.
exons 13–18 on der(X) (fig. 3C, right panel). These re-
sults clearly indicate that STK9 exons 1–10 are tran-
scribed in patient 1. The truncated RNA would encode
a protein of 275 amino acids, which may retain some
functional properties.
In patient 2, the breakpoint has been located between
exons 1 and 1a (figs. 3A and 3B). RT-PCR experiments
with exon 2 and 3 primers failed to detect any STK9
RNA. This was also true for another set of 3′ end–specific
STK9 RT-PCR primers (fig. 3C and results not shown).
As a result, this patient does not express any detectable
STK9 RNA of the isoform I (originating from exon 1).
Expression of the STK9 isoform II (originating from
exon 1a) could not be tested, because this isoform is not
expressed in lymphoblasts. Precise position of the chro-
mosome 6 breakpoint was not determined.
STK9 and ARX are separated by ∼5 Mb of genomic
sequence, as estimated from the Ensembl Human Ge-
nome assembly (STK9 being at postion ∼18.4 Mb and
ARX at position ∼23.8 Mb). In patient 1, ARX ex-
pression was identical to that of control fibroblasts (data
not shown); therefore, a position effect is unlikely. The
ARX gene is not transcribed in lymphoblastoid cell lines;
thus, the analysis could not be performed in patient 2.
SSCP screening of DNA of patient 2 for the ARX gene
yielded no mutations.
In patient 1, we have also identified the chromosome
7 breakpoint by using adaptor-ligated PCR. It lies be-
tween exons 4 and 5 of the formerly predicted gene
LOC168637. However, using several primer sets in RT-
PCR, we could not amplify any predicted exon on fetal
brain RNA, suggesting that this gene is either not ex-
pressed in brain or is not real. The latter possibility
is further supported by negative BLAST searches of
LOC168637 against ESTs in public databases. More re-
cently, the gene prediction of LOC168637 has been re-
moved from the database. Therefore, it is very unlikely
that a gene on chromosome 7 is interrupted by the
breakpoint.
To date, only a few studies describe short sequence
motifs involved in human balanced chromosomal re-
arrangements (Giacalone and Franke 1992; Nothwang
et al. 2000; Bonaglia et al. 2001). Analysis of the junc-
tion fragments in patient 1 revealed that the transloca-
tion is balanced with loss of a 3-bp sequence that is a
common motif at the rearrangement sites of chromo-
somes X and 7 (fig. 3D).
STK9 Screening in Families with X-Linked WS/ISSX
Prior to the identification of the ARX gene as the
major cause of the X-linked WS/ISSX (Strømme et al.
2002b), we used SSCP and direct sequencing to screen
the STK9 gene in the four previously published families
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with ISSX (one reported by Strømme et al. [1999], two
reported by Claes et al. [1997], and one reported by
Bruyere et al. [1999]) and the family with XMESID (X-
linked myoclonic epilepsy with spasticity and intellectual
disability) reported by Scheffer et al. (2002). Further-
more, no disease-causing mutations were identified in
the family B reported by Claes et al. (1997), which was
also negative when screened for mutations in the ARX
gene. We have detected only one cSNP, at position 2593
(2593ArC, exon 16), which results in the amino acid
change Q791P. This cSNP was detected on 20% of a
panel of 50 control chromosomes on which it was tested
(results not shown).
Discussion
Disease-associated balanced chromosome rearrange-
ments form a visible bridge between genotype and phe-
notype and have been instrumental in the identification
of numerous disease genes. In the present study, we have
characterized two female patients, one with a 46,X,t(X;7)
(p22.3;p15) and the other with a 46,X,t(X;6)(p22.3;q14)
apparently balanced translocation. The patients pre-
sented with a seemingly identical phenotype, comprising
early-onset severe infantile spasms with profound global
developmental arrest and hypsarrhythmia on the EEG.
In patient 1, cranial MRIs in early childhood were nor-
mal, but she showed ventricular enlargement and hy-
poplasia of the corpus callosum, cerebellum, and white
matter at age 6 years. Patient 2 died at age 3 years; results
of cranial CT and MRI were normal. Such diagnoses as
Aicardi syndrome (a rare, congenital X-linked disorder
with the classic features of infantile spasms, callosal
agenesis, and pathognomonic chorioretinal lacuna) and
ISSX or X-linked WS were considered.
Cytogenetic investigations showed skewed X inacti-
vation in both patients, which was later confirmed by
molecular studies. The X chromosomal rearrangements
disrupt STK9 in both patients. In particular, the break-
point in patient 2 is in the most 5′ end of STK9, and
the major transcript is completely lacking, which further
suggests that in normal female somatic cells STK9 is
subject to X-inactivation.
The truncation of STK9 in these patients, together
with normal ARX expression and the absence of the
ARX gene mutations, strongly suggests that, in these
patients, the disease was caused by either complete (pa-
tient 2, isoform I) or partial (patient 1, isoforms I and
II) loss of STK9 protein function. Although in patient
1 either of the two isoforms is affected (truncated) by
the translocation, in patient 2 it would be at least iso-
form I (containing exon 1) that is completely missing.
The expression of the isoform II, which is likely to be
transcribed from a different STK9 promoter ∼12 kb
proximal to the breakpoint of patient 2, could not be
tested, because this isoform is not transcribed in lym-
phoblasts (the only cell line available from patient 2).
Position effect of the translocation on the promoter of
STK9 isoform II can also be considered. In the absence
of data on STK9 isoform II expression in patient 2, we
can only speculate about the biological significance of
this isoform. However, on the basis of the much lower
expression level of isoform II and the different expres-
sion pattern of both STK9 isoforms, it is highly unlikely
that isoform II (if expressed in patient 2) would have
been able to compensate for the lack of the major STK9
isoform I.
The autosomal breakpoints most likely do not con-
tribute to the phenotype, because they are on different
chromosomes. In patient 1, the chromosome 7 break-
point does not directly disrupt an obvious gene and lies
distal to the 3′ end of GLI3 (the gene mutated in Greig
cephalopolysyndactyly syndrome [MIM 165240]) and
proximal to the 3′ end of INHBA (MIM 147290), which
may play a role in craniofacial development. The au-
tosomal breakpoint in patient 2 has not been mapped
in detail.
STK9 mutation analysis in all four published families
with ISSX (one reported by Strømme et al. [1999], two
reported by Claes et al. [1997], and one reported by
Bruyere et al. [1999]) was negative, including the family
B reported by Claes et al. (1997), which is the only
ARX-negative family with ISSX (Strømme et al. 2002b).
Taken together with our previous findings of ARX mu-
tations causing ISSX (Bienvenu et al. 2002; Strømme et
al. 2002b), these studies provide strong evidence that
the etiology of ISSX is heterogeneous. Provided that the
family B of Claes et al. (1997) does not have a mutation
in either STK9 (the present study) or ARX (Strømme
et al. 2002b) genes, we may speculate the existence of
yet another ISSX locus on Xp.
Additional circumstantial evidence implicating the
STK9 gene in epilepsy comes from the recent article by
Huopaniemi et al. (2000). These authors performed a
mutation search in Danish patients with retinoschisis
and found a 136-kb deletion in two affected siblings
with typical retinoschisis. The 3′ UTR region of STK9
overlaps with the 3′ UTR of the XLRS1 gene, which is
the gene implicated in X-linked juvenile retinoschisis
(XLRS). The rearrangement partly deleted XLRS1 and
also PPEF-1 (protein phosphatase gene with EF cal-
cium-binding domain) and truncated the 3′ end of STK9,
including the last coding exon. One affected brother
had epilepsy in addition to retinoschisis. It is unclear at
present whether epilepsy in this case is related to the
truncated STK9 gene and whether other alterations in
STK9 can lead to a less severe form of ISSX.
STK9 was isolated in the course of a transcriptional
mapping effort in the Xp22 region (Montini et al.
1998). Northern analysis revealed transcription in sev-
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eral tissues, including fetal and adult brain. We have
revised the genomic structure of the STK9 gene. Several
differences from the previous report by Montini et al.
(1998) were detected. One of these differences is that
the STK9 gene contains at least 23 exons, the first three
exons being untranslated and representing two STK9
isoforms most likely transcribed from two different pro-
moters (while both maintain the same ORF; see fig. 3A).
The predicted STK9 protein belongs to the large fam-
ily of eukaryotic protein kinases that are related by the
highly conserved kinase domain, which comprises 250–
300 amino acids. Protein kinases have been involved
very frequently in the pathogenesis of genetic disorders.
At present we can speculate on STK9 function only by
virtue of sequence comparison with known homologs.
Its kinase domain is most closely related to human
KKIAMRE and KKIARLE and their orthologs (Montini
et al. 1998). These proteins are members of the mitogen-
activated protein (MAP) kinase family that is related to
cell-division cycle 2. MAP kinases are important regu-
lators of synaptic plasticity in neurons. However, human
KKIARLE is expressed in fibrous astrocytes in the white
matter, in perivascular and subpial spaces, and in Berg-
mann glia in the cerebellum but not in neurons (Yen et
al. 1995). In contrast, its mouse and rat counterparts
are expressed in neurons in various brain regions, in-
cluding the cerebral cortex and hippocampus, as evi-
denced by immunohistochemistry (Gomi et al. 1999;
Sassa et al. 2000). KKIAMRE very likely plays a role
in learning and memory and has been shown to be phos-
phorylated by MEK1, a protein kinase that activates
MAP kinases in vitro (Taglienti et al. 1996; Gomi et al.
1999). These results suggest that STK9 protein may play
a role in the MAP kinase cascade, although experimen-
tal evidence is needed to prove this hypothesis. In ad-
dition to this, BLAST searches revealed 44% identity
and 64% similarity to cell division protein kinase 5 (t
protein kinase II catalytic subunit) and 43% identity
and 63% similarity to cell division protein kinase 2 (p33
protein kinase). At present, we do not know the sig-
nificance of the similarities between STK9 and other
kinases. Identification of substrates for STK9 will help
to determine the importance of these similarities.
Taken together, our observations indicate that STK9
is a new ISSX locus and is the second gene implicated
in infantile spasms, suggesting that the etiology of ISSX
is heterogeneous. The overall contribution of STK9 mu-
tations in ISSX remains to be determined. Ongoing stud-
ies will shed more light on the role of STK9 and its
substrate(s) and signaling pathway in the brain and will
help to unravel the pathogenic mechanisms of ISSX.
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